Posttransplantation antibody mediated rejection: New insights into mechanism, treatment and protective strategies

Chinese Medical Journal

Volumn 124, Issue 5, 2011, Pages 646-648

  Mao, You Ying ^a   Chen, Jiang Hua ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; COMPLEMENT COMPONENT C4D; IMMUNOGLOBULIN; RITUXIMAB; T LYMPHOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIBODY DETECTION; CLINICAL EFFECTIVENESS; DESENSITIZATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOSE RESPONSE; DRUG MEGADOSE; EDITORIAL; GENETIC TRANSCRIPTION; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOGENESIS; INTERMETHOD COMPARISON; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; PATIENT MONITORING; RISK REDUCTION; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS;

EID: 79952523700     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.05.002     Document Type: Editorial

References (20)

1. Chen JH, Xie WQ, Wang HP, Jin J, Wu JY, He Q. C4d as a significant predictor for humoral rejection in renal allografts. Clin Transplant 2005; 19: 785-791.
2. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria -- an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
3. Lefaucheur C, Loupy A, Hill JS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
4. Lefaucheur C, Nochy D, Hill GS, Suberbielle-Boissel C, Antoine C, Charron D, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832-841.
5. Bachler K, Amico P, Honger G, Bielmann D, Hopfer H, Mihatsch MJ, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254-1262.
6. Alvarez-Marquez A, Aguilera I, Gentil MA, Caro JL, Bernal G, Fernandez Alonso J, et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009; 87: 94-99.
7. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
8. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
9. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibodymediated rejection. Curr Opin Organ Transplant 2010; 15: 42-48.
10. Bohmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7: 117-1121.
11. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
12. Mulley WR, Hudson FJ, Tait BD, Skene AM, Dowling JP, Kerr PG, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87: 286-289.
13. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
14. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
15. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
16. Loupy A, Suberbielle-Boissel C, Zuber J, Anglicheau D, Timsit MO, Martinez F, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403-1410.
17. Yin H, Hu XP, Li XB, Liu H, Wang W, Ren L, et al. Protein A immunoadsorption combined with rituximab in highly sensitized kidney transplant recipients. Chin Med J 2009; 122: 2752-2756.
18. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
19. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
20. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.